pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,657 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT797Endpoints598BioPharma Dive230onclive165BioSpace68Fierce Biotech68raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
    A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024
    STAT · 1mo ago↗ source
  • DOJ reaches second settlement on youth gender care
    A new era of American sunscreen, NIAID taps new acting director, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Ethyreal lands $101M to treat both Graves' and thyroid eye disease
    A biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves' disease and thyroid eye disease, and the startup plans to enter the…
    Endpoints · 1mo ago
← prev
page 31 of 67
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
    Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of…
    Endpoints · 1mo ago↗ source
  • Are Republicans turning against medications for treating opioid addiction?
    Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.
    STAT · 1mo ago↗ source
  • STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
    In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
    STAT · 1mo ago↗ source
  • Opinion: Even in abortion-protecting states, teens face unnecessary barriers to care
    “Legal protection for abortion does not mean equitable access for minors,” a pediatrics resident writes.
    STAT · 1mo ago↗ source
  • Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72
    “I know what I’m getting into”: Dawn Zuidgeest-Craft on starting medical residency at almost 73.
    STAT · 1mo ago↗ source
  • Parabilis' $670M IPO sets new biotech record, will fund cancer drug
    Despite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever s…
    Endpoints · 1mo ago↗ source
  • STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
    The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.
    STAT · 1mo ago↗ source
  • STAT+: Trump’s health care affordability czar takes aim at hospitals
    Plus a buried alcohol study gets published, and a Biosecure update.
    STAT · 1mo ago↗ source
  • Diabetes Association in uproar after members expelled from annual meeting over protest of NIH cuts
    The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts.
    STAT · 1mo ago↗ source
  • FDA OKs first new sunscreen ingredient in more than 25 years
    Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.
    STAT · 1mo ago↗ source
  • Eli Lilly's claims data deadline may kick off new 340B fight
    Eli Lilly’s deadline has passed for hospitals to comply with its new 340B claims data policy, and for now the pharma company is staying mum on its next steps. But just because Lilly is declining ...
    Endpoints · 1mo ago↗ source
  • Grace Science says FDA bottleneck jeopardizes rare disease therapy
    Grace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line. Co-founded by Nobel laureate Carolyn Bertozzi…
    Endpoints · 1mo ago↗ source
  • A different approach to lowering healthcare costs
    Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...
    Endpoints · 1mo ago↗ source
  • Trump administration warns more than 500 hospitals to provide more price information or face fines
    The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.
    STAT · 1mo ago↗ source
  • How K Health moved AI chatbots into hospitals
    Startups that fashion themselves as AI doctors that patients can chat with have gained traction over the last year. One of these startups, K Health, began in 2016 as a symptom checker ...
    Endpoints · 1mo ago↗ source
  • Gilead and Merck’s latest trial success and flop
    AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: NIAID appoints new acting director after weekslong questions over leadership
    The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
    STAT · 1mo ago↗ source
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…
    Endpoints · 1mo ago↗ source
  • Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
    Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…
    Endpoints · 1mo ago↗ source
  • Endpoints Women in Biopharma: Nominate for 2026
    Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…
    Endpoints · 1mo ago↗ source
  • Pharma and biotech salaries: Top-paying companies of 2025
    The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
    GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
    STAT · 1mo ago↗ source